Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
to Rezurock (belumosudil) for treating chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and above weighing at least 40 kg. This conditional approval is contingent on completion of a confirmatory, randomized, controlled study. Rezurock is to be used when other treatments offer limited benefit, aren't suitable, or have been exhausted. The approval in the EU was expected, as in January 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion, recommending the conditional marketing authorization of Rezurock for the given indication. SNY's Price Performance Year to date, shares of Sanofi have declined 3.8% compared with the industry's decrease of 4.7%. Zacks Investment Research Image Source: Zacks Investment Research More on the EU Nod for SNY's Rezurock The approval of Rezurock in the EU was based on safety and efficacy data from various clinical studies and real-world evidence,
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host diseaseGlobeNewswire
- Sanofi Oncology And Rare Disease Updates Spark Fresh Valuation Interest [Yahoo! Finance]Yahoo! Finance
- Sanofi eczema drug weighed down by mixed results, safety concerns [Yahoo! Finance]Yahoo! Finance
- Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patients [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 3/31/26 - Form 6-K
- 3/24/26 - Form 6-K
- 3/10/26 - Form 6-K
- SNY's page on the SEC website